Table 1.

Effect of patient VDR polymorphisms on the impact of vit D on cGvHD incidence

Overall cGvHD incidence (1 year)Moderate–severe cGvHD incidence (1 year)
Cumulative incidenceCumulative incidence
% (95% CI)% (95% CI)
GenotypeVit DNo vit DPVit DNo vit DP
PolymorphismN (Vit D/no vit D)(n = 71)(n = 36)(n = 71)(n = 36)
Incidence of cGvHD depending on the genotype
FokICC (20/16)47.6 (24–67)53.3 (24–70)0.728.6 (11.1–0.49)33.3 (11.2–57.6)0.6
CT (28/10)22.5 (8.8–39)80 (30.8–95)0.000411 (2.7–26)60 (22–84.2)0.001
TT (9/6)22 (2.8–53)50 (5.5–84.7)0,2822 (2.8–0.53)50 (2.9–58)0.28
Incidence of cGvHD depending on the most frequent haplotypes
GGT/GGT16/814.3 (1.9–35.9)75 (20–95)0.000713.3 (1.9–35.7)75 (20–95)0.002
GGT/ATC15/640.4 (11–69)33.3 (2.5–72.2)0.824.9 (4.4–53.7)16.7 (3.3–58.5)0.8
ATC/ATC5/640 (3.1–78.6)50 (6.9–83.6)0.920 (0.4–62)33.3 (2.9–71)0.6
Incidence of cGvHD depending on the presence/absence of the ATC haplotype
ATC Yes30/1542.2 (23.3–59.9)53.3 (24.4–75.6)0.542.2 (23.3–59.9)53.3 (24.4–75.6)0.5
ATC No28/1622.2 (8.8–39.5)68.8 (37.7–86.6)0.000521.6 (8.5–38.6)50 (23.1–72)0.03